US 12,187,789 B2
Biopharmaceutical compositions
Myrna A. Monck, Waltham, MA (US); Narendra B. Bam, King of Prussia, PA (US); Jennifer Dally, King of Prussia, PA (US); and Michelle Spatara, King of Prussia, PA (US)
Assigned to GlaxoSmithKline Intellectual Property (No.2) Limited, (GB)
Filed by GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED, Stevenage (GB)
Filed on Apr. 30, 2024, as Appl. No. 18/650,526.
Application 16/806,071 is a division of application No. 15/754,768, granted, now 10,870,695, previously published as PCT/IB2016/055012, filed on Aug. 22, 2016.
Application 18/650,526 is a continuation of application No. 17/881,988, filed on Aug. 5, 2022.
Application 17/881,988 is a continuation of application No. 17/684,907, filed on Mar. 2, 2022, granted, now 11,459,384.
Application 17/684,907 is a continuation of application No. 17/373,537, filed on Jul. 12, 2021, granted, now 11,299,541.
Application 17/373,537 is a continuation of application No. 16/806,071, filed on Mar. 2, 2020, abandoned.
Claims priority of provisional application 62/249,497, filed on Nov. 2, 2015.
Claims priority of provisional application 62/247,906, filed on Oct. 29, 2015.
Claims priority of provisional application 62/240,131, filed on Oct. 12, 2015.
Claims priority of provisional application 62/209,000, filed on Aug. 24, 2015.
Prior Publication US 2024/0294628 A1, Sep. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61P 11/02 (2006.01); A61P 11/06 (2006.01)
CPC C07K 16/244 (2013.01) [A61P 11/02 (2018.01); A61P 11/06 (2018.01); C07K 2317/24 (2013.01); C07K 2317/40 (2013.01); C07K 2317/90 (2013.01); C07K 2317/94 (2013.01)] 22 Claims
 
1. A composition comprising:
(a) mepolizumab comprising a heavy chain amino acid sequence as shown in SEQ ID NO: 1 and a light chain amino acid sequence as shown in SEQ ID NO: 2; and
(b) acidic antibody variants of mepolizumab wherein the acidic antibody variants comprise a heavy chain amino acid sequence as shown in SEQ ID NO: 1, and a light chain amino acid sequence as shown in SEQ ID NO:2, except that residue N31 of SEQ ID NO: 2 is deamidated, and wherein said acidic variants are present in the composition in an amount from 3.3% to 17.4%, as determined by peptide mapping LC MS/MS.